SOVREMENNAYA PEDIATRIYA.2016.4(76):85-90; doi10.15574/SP.2016.76.85 

Correction of intestinal microbiocenosis disorders in children with irritable bowel syndrome 

Yaroshevskaya T. V., Ilchenko S. I., Sapa N. B., Kramarenko L. N.

SI «Dnіpropetrovsk Medical Academy, Ministry of Health of Ukraine»

MI «Dnipropetrovsk Children's City Clinical Hospital №2 DRC» 

Objective: To study the efficacy and safety of developed therapy complexes based on the modern Prema symbiotic during the irritable bowel syndrome (IBS) in children with clinical and laboratory manifestations of large intestine dysbiosis.

Patients and methods. A total of 35 children with IBS (18 boys and 17 girls) in the age from 3 to 17 years (average age of 6.2±4.1 years) were under observation. For all patients was assigned comprehensive differentiated treatment according to the identified pathology. Additionally, in order to correct the identified dysbiotic violations was appointed «Prema» symbiotic, containing Lactobacollusrhamnosus GG strains and fructo-oligosaccharides.

Results. As a result of treatment symptoms of intestinal dyspepsia, abdominal pain syndrome and the clinical manifestations of the syndrome digestive disorders were quickly jugulated and also improved microbiological characteristics of feces. In children with skin manifestations of allergy was marked the decrease of its severity.

Conclusions. The necessary link in the complex therapeutic measures for children with IBS is to correct intestinal dysbiosis. The efficacy and safety of «Prema» preparation is proved. Therefore, it can be recommended as a part of complex therapy for children with IBS.

Key words: children, irritable bowel syndrome, dysbiosis, probiotic, Lactobacillusrhamnosus GG.

REFERENCES

1. Belousova OYu. 2015. Algoritm naznacheniya probiotikov u detey. Zdorove Ukrainyi. 3(34): 10—11.

2. Belousova OYu. 2011. Disbakterioz kishechnika kak faktor riska razvitiya hronicheskih zabolevaniy kishechnika u detey. Zdorove rebenka. 1(28): 73—75.

3. Havkin AI, Fayzullina RA, Belmer SV i dr. 2014. Diagnostika i taktika vedeniya detey s funktsionalnyimi zaporami. Voprosyi prakticheskoy pediatrii. 9; 5: 62—76.

4. Kopanev YuA, Sokolov AL. 2002. Disbakterioz kishechnika: mikrobiologicheskie, immunologicheskie aspektyi mikrobiologicheskih narusheniy u detey. Moskva: 147.

5. Maydannik VG. 2013. AntibiotikoAassotsiirovannaya diareya u detey. Kyiv: 38.

6. Shane AL, Cabana MD, Vidry S et al. 2010. Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes. 1(4): 243—253. http://dx.doi.org/10.4161/gmic.1.4.12707; PMid:21327031 PMCid:PMC3023606

7. Horvath A, Dziechciarz P, Szajewska H. 2011. Meta-Aanalysis: Lactobacillus rhamnosus GG for abdominal pain Arelated functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 33(12): 1302—1310. http://dx.doi.org/10.1111/j.1365-2036.2011.04665.x; PMid:21507030

8. Floch MH, Walker WA, Madsen K et al. 2011 Recommendations for probiotic use — 2011 update. J Clin Gastroenterol. 45: 168—171. http://dx.doi.org/10.1097/MCG.0b013e318230928b; PMid:21992958

9. Ringel Y, Quigley EMM, Lin HC. 2012. Using probiotics in gastrointestinal disorders. Am J Gastroenterol. 1(1): 34—40. http://dx.doi.org/10.1038/ajgsup.2012.7

10. Whelan K, Myers CE. 2010. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clinc Nutr. 91(3): 687—703. http://dx.doi.org/10.3945/ajcn.2009.28759; PMid:20089732